Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

DYAX:US

27.9700 USD 0.4600 1.62%

As of 20:10:00 ET on 04/17/2015.

Snapshot for Dyax Corp (DYAX)

Open: 28.2000 Day's Range: 27.5800 - 28.5400 Volume: 1,791,560
Previous Close: 28.4300 52wk Range: 6.0500 - 30.5500 1-Yr Rtn: +315.60%

Stock Chart for DYAX

No chart data available.
  • DYAX:US 27.9700
  • 1D
  • 1M
  • 1Y
28.4300
Interactive DYAX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for DYAX

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.1000
Est. EPS (USD) (12/2015) -0.1810
Est. PEG Ratio -
Market Cap (M USD) 4,029.42
Shares Outstanding (M) 144.06
30 Day Average Volume 2,851,228
Price/Book (mrq) 36.1279
Price/Sale (ttm) 45.8950
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/29/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for DYAX

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for DYAX

Dyax Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of antibodies, small proteins and peptides as therapeutic products for unmet medical needs, particularly in the areas of inflammation and oncology. The Company currently has two recombinant proteins, DX-88 and DX-890 in phase II clinical trials.

Gustav A ChristensenPresident/CEOGeorge V MigauskyExec VP/CFO
Burt A AdelmanExec VP/Chief Medical OfcrTodd BazemoreExec VP/Chief Commercial Ofcr
More Company Profile & Key Executives for DYAX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil